drugset / Trial / NCT07607561
Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration
RandomizedParallel-groupDouble-blindTreatment
Summary
Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).
Timeline
- Start
- 2026-11-01
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 0.04 % | Other |
| Subject | Axitinib | Small molecule | 0.08 % | Other |
| Subject | Axitinib | Small molecule | 0.084 mg | Other |
| Subject | Axitinib | Small molecule | 0.168 mg | Other |